Sign in
Taking people in United StatesNo phase

Free Glucose Sensors for Adults with Poorly Controlled Type 2 Diabetes

Studies free continuous glucose monitors in adults with poorly controlled type 2 diabetes.

Key facts

Who runs it
Yale University
Where
New Haven, United StatesSee the site
Trial code
Registry title
Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
Status
Recruiting
People taking part
17 people, planned
Started
12 Nov 2024
Planned end
Jun 2026
Type of study
Interventional
Treatments tested
  • Continuous Glucose Monitor (CGM)
Record updated
3 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with poorly controlled type 2 diabetes who use insulin and cannot afford CGM sensors. They are patients of Fair Haven Community Health Care.

Age
18 years or older
Sex
All sexes can join
Disease stage
Type 2 diabetes with an A1c of 8.0 or higher within two weeks of enrollment
Earlier treatment
On insulin for at least one year, with or without other diabetes medicines
Biomarker or test result
A1c of 8.0 or higher within two weeks of enrollment

Main reasons for not taking part

  • Never used insulin
  • Diabetic ketoacidosis (DKA) in the past 6 months
  • End-stage renal disease (ESRD)
  • Medical reason not to use a CGM
  • Insurance that would pay enough for the person to buy CGM sensors

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with type 2 diabetes mellitus
  • A1c greater than or equal to 8.0 within two weeks of the time of enrollment
  • On insulin for at least one year +/- other antihyperglycemics
  • Ability and willingness to wear CGM for 14-day periods throughout the trial period
  • Ability and willingness to comply with provider-directed adjustments to medication regimen
  • Inability to afford CGM sensors; A note on Vulnerable Populations: Many of FHCHC's patients are economically disadvantaged and of minority backgrounds; the clinic's patient base may be considered to constitute a vulnerable population. As such, recruitment and enrollment will be conducted within a vulnerable population. The nature of the study requires this, and the results are intended to directly benefit this population through the potential for improved glycemic control and quality of life

Who cannot take part

  • Diabetic ketoacidosis (DKA) in previous 6 months
  • End-Stage Renal Disease (ESRD)
  • Insulin naïve
  • Contraindications to CGM use
  • Active insurance plan that would provide enough of a subsidy for participant to feasibly purchase CGM sensors
  • Pregnancy

Where in United States

  • Fair Haven Community Health Care (FHCHC)New Haven, United StatesContact: Justin A Dower, MDTaking people

About the trial

What the trial wants to find out

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

The group in the trial

  • Poorly Controlled Type 2 Diabetes- CGMTreatment being tested

    Participants will have CGM sensor placed at first visit and will be worn for 12 weeks. Sensor must be scanned 3 times daily. Adjustments to medication regimen will be recommended at 6 weeks. Follow-up appointments will be at 12 weeks and 24 weeks.

    Treatment: Continuous Glucose Monitor (CGM)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
CGMs for All: Studying the Impact of Expanding CGM Access
Plain-language title
Free Glucose Sensors for Adults with Poorly Controlled Type 2 DiabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 December 2025